Global rates of diagnosed autism spectrum disorder (ASD) and attention deficit/hyperactivity disorder (ADHD) have risen substantially over the past two decades, prompting debate within the clinical and public health communities about whether this trajectory reflects a genuine epidemiological shift or, more precisely, the correction of decades of systematic underdiagnosis. The weight of current evidence, as synthesized in a recent analysis published in The BMJ, supports the latter interpretation: rising prevalence figures reflect improved recognition of neurodivergence, particularly among populations that diagnostic frameworks have historically failed to capture.

Prevalence Rates and Cross-National Comparisons

Systematic assessment of ASD and ADHD prevalence using health and education data drawn from millions of participants across multiple nations has produced a notable finding. Despite frequent assumptions that diagnostic rates vary considerably by geographic and cultural context, current prevalence estimates in the United States, the United Kingdom, and Sweden demonstrate close alignment. This convergence across health systems with distinct diagnostic infrastructures, referral pathways, and clinical cultures suggests that the observed increases are not artifacts of any single national policy or clinical trend. Rather, they reflect a broader, international recalibration of diagnostic thresholds and recognition practices.

This convergence carries methodological consequence. When prevalence figures across disparate systems align, researchers can be more confident that they are measuring a stable underlying population of neurodivergent individuals rather than a rate inflated by diagnostic fashion or healthcare system incentives. The data from these large-scale health and education registries therefore provide a more reliable baseline from which clinicians and policymakers can interpret temporal trends.

Diagnostic Criteria and the Failure to Capture Non-Stereotypical Presentations

A central driver of historical underdiagnosis has been the construction of diagnostic criteria themselves. The tools used to identify both ASD and ADHD were developed predominantly from research conducted on male, white, and relatively socioeconomically advantaged populations. As a result, the phenotypic profiles embedded in those criteria reflected a narrow and non-representative sample of the broader neurodivergent population.

Non-stereotypical presentations, which diverge from the prototypical clinical picture encoded in earlier versions of the Diagnostic and Statistical Manual of Mental Disorders (DSM) and the International Classification of Diseases (ICD), have been systematically missed. Individuals whose neurodivergence manifests differently, whether due to learned compensatory strategies, cultural variation in behavioral expression, or the compounding effects of other social factors, have faced substantially higher barriers to accurate diagnosis. The clinical consequences of this failure have been considerable: delayed intervention, inappropriate treatment for misattributed symptoms, and reduced access to educational and occupational accommodations.

Improved recognition of these non-stereotypical presentations is now considered a primary factor in the observed increases in diagnosed prevalence. This is not a population producing more neurodivergent individuals. It is a clinical and research infrastructure becoming better calibrated to identify neurodivergent individuals who were always present.

Gender and the Narrowing Diagnostic Ratio

Historical data indicated a marked male predominance in both ASD and ADHD diagnoses. For ASD, male-to-female ratios of approximately 4:1 were widely cited in older epidemiological literature. For ADHD, similar imbalances were reported. Emerging evidence from both research cohorts and clinical practice now indicates that this ratio is narrowing at a pace that warrants serious attention.

In the case of ASD specifically, data suggest that the gender ratio may approach parity by adulthood. This finding has substantial clinical implications. If equal numbers of males and females meet diagnostic criteria for ASD when assessed in adulthood using appropriately sensitive tools, then the historical gender disparity cannot be attributed to a genuine difference in underlying prevalence. It must instead be attributed to differential rates of recognition, referral, and diagnosis during childhood and adolescence.

The proposed mechanism is well-supported by qualitative and quantitative research alike. Female-presenting individuals with ASD and ADHD frequently engage in masking, a process by which they consciously or unconsciously camouflage their neurodivergent traits to conform to social expectations. Masking behavior reduces the visibility of symptoms to clinicians, teachers, and caregivers who are trained to identify presentations more common in male patients. As a result, female-presenting individuals often reach diagnostic thresholds later, if at all, and frequently accumulate psychiatric comorbidities, including depression and anxiety disorder, in the interim.

The narrowing of the gender ratio in contemporary prevalence data therefore reflects, in part, the development of diagnostic tools and clinical approaches better equipped to identify masked or non-stereotypical presentations. It also reflects increased advocacy and self-referral among women and gender-diverse individuals who have encountered information about ASD and ADHD in contexts outside traditional clinical settings.

Intersectionality: Ethnicity, Socioeconomic Status, and Marginalised Communities

The evidence is explicit that increased awareness of neurodivergence within marginalised groups is a primary driver of contemporary prevalence increases. This framing demands careful disaggregation. Marginalised status, as it intersects with neurodivergence, does not imply greater biological susceptibility to ASD or ADHD. It implies that individuals from ethnic minority backgrounds, from lower socioeconomic strata, and from communities with historically limited access to specialist healthcare have been diagnosed at substantially lower rates than their actual prevalence would predict.

Multiple mechanisms account for this disparity. Diagnostic tools calibrated to majority-population presentations perform less reliably when applied across cultural contexts in which behavioral norms, communication styles, and expressions of distress differ. Clinicians operating with implicit assumptions about which populations present with ASD or ADHD may exhibit referral bias, directing specialist evaluations preferentially toward patients who match prototype expectations. Access barriers, including the cost of private assessment in systems where public wait times are prohibitive, further concentrate diagnosed prevalence in advantaged populations.

As awareness has grown and as advocacy organisations representing diverse communities have expanded their reach, referral and diagnosis rates among previously underserved populations have increased. This increase is not an artifact of diagnostic inflation. It is the correction of a systematic failure.

For clinicians practicing in Hawaii and across the Pacific region, this dimension of the research carries particular relevance. Pacific Islander communities face documented disparities in access to specialist pediatric and psychiatric services. The intersection of geographic isolation, cultural variation in the expression of neurodevelopmental traits, and diagnostic tools developed without reference to Pacific populations represents a compounding liability. Prevalence data for ASD and ADHD among Native Hawaiian and Pacific Islander children remain less robust than those available for other ethnic groups in the United States. Addressing that gap requires both investment in population-specific epidemiological research and the development of culturally adapted diagnostic instruments.

The Alternative Position and Its Limitations

The BMJ analysis presents both sides of the debate. The opposing argument, advanced by other commentators in the same publication, holds that at least some portion of the prevalence increase reflects genuine overdiagnosis driven by lowered diagnostic thresholds, broadened criteria following successive DSM revisions, or social contagion effects mediated by digital information ecosystems.

This position merits consideration, and the evidence base does not permit its categorical dismissal. The broadening of ASD diagnostic criteria in DSM-5 relative to its predecessor did alter which presentations qualified for a diagnosis. The expansion of ADHD criteria to include adult presentations similarly expanded the eligible population. These are real changes with real effects on prevalence statistics.

However, the claim that overdiagnosis constitutes the primary driver of rising prevalence rates is not well-supported by the cross-national data. If broader criteria or social contagion were the dominant mechanism, one would expect prevalence rates to diverge more substantially across health systems with different diagnostic cultures and different levels of social media penetration. The observed convergence between the United States, United Kingdom, and Sweden does not support a narrative centered on diagnostic inflation as the primary explanation.

Furthermore, the documented underdiagnosis of women, ethnic minorities, and lower socioeconomic groups provides a more parsimonious explanation for much of the observed increase. When populations that were systematically excluded from diagnosis begin receiving appropriate evaluation and support, prevalence rates rise. That rise represents progress, not pathologization.

Clinical and Policy Implications

The implications of this evidence base for clinical practice and health policy are several. Diagnostic tools currently in widespread use require ongoing validation across diverse populations, with particular attention to their performance in non-majority ethnic groups, female-presenting individuals, and adults who present with a history of compensation strategies.

Training programs for pediatricians, psychiatrists, psychologists, and primary care physicians must incorporate updated understanding of non-stereotypical ASD and ADHD presentations. Clinicians who rely on prototypical presentations, such as the hyperactive male child with overt behavioral disruption, will continue to miss the substantial proportion of neurodivergent individuals whose profiles differ.

Health systems must also address structural barriers to timely diagnosis. In contexts where specialist wait times extend to multiple years, as is currently the case in much of the United Kingdom’s National Health Service and in many rural and underserved areas of the United States, the populations least able to navigate those barriers will continue to be underserved. Hawaii’s geography compounds this problem for residents of neighbor islands who lack access to the specialist services concentrated on Oahu.